ClinicalTrials.Veeva

Menu

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

K

Klus Pharma

Status and phase

Enrolling
Phase 2

Conditions

Solid Tumor

Treatments

Drug: SKB264
Drug: Pembrolizumab

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT05642780
SKB264-II-06

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.

Enrollment

240 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subjects with Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 .
  2. Subjects with expected survival ≥ 3 months.
  3. Cohort A: Subjects with recurrent or metastatic cervical cancer
  4. Cohort B: Subjects with locally advanced or metastatic urothelial carcinoma
  5. Cohort C: Subjects with recurrent ovarian cancer
  6. Cohort D: Subjects with metastatic prostate cancer
  7. Subjects have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
  8. Subjects able to provide tumor blocks or slides for biomarker test.
  9. Subjects have relatively good organ function and bone marrow function.
  10. Subjects must have recovered from all toxicities from previous therapy with the exception of toxicities not considered a safety risk.
  11. Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  12. Subject is capable of giving signed informed consent.
  13. Cohort E: Subjects with advanced endometrial cancer.

Exclusion criteria

  1. Subjects with active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis are not eligible.
  2. Subjects who suffer from cardiovascular diseases of clinical significance.
  3. Subjects with serious and/or uncontrolled concomitant diseases.
  4. Subjects diagnosed active hepatitis B or hepatitis C.
  5. Subjects have known human immunodeficiency virus (HIV) infection that is not well controlled.
  6. Subjects with known active tuberculosis.
  7. Known allergy or hypersensitivity to pembrolizumab or SKB264, or the excipients of pembrolizumab or SKB264.
  8. Subjects with history of allogeneic tissue/solid organ transplant.
  9. Subjects previously treated with TROP2 targeted therapy.
  10. Subjects who are vaccinated with live vaccine within 30 days before the first dose, or plan to be vaccinated with live vaccine during the study period.
  11. Subjects participating in another clinical study, unless it is an observational (non-intervention) clinical study or the follow-up period of an intervention study.
  12. The Investigator considers other situations that will interfere with the evaluation of the study intervention or the safety of the subjects or the interpretation of the results of the study.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 5 patient groups

cohort A
Experimental group
Description:
subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
Treatment:
Drug: Pembrolizumab
Drug: SKB264
cohort B
Experimental group
Description:
subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
Treatment:
Drug: Pembrolizumab
Drug: SKB264
cohort C
Experimental group
Description:
subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
Treatment:
Drug: Pembrolizumab
Drug: SKB264
cohort D
Experimental group
Description:
subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
Treatment:
Drug: Pembrolizumab
Drug: SKB264
Cohort E
Experimental group
Description:
subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
Treatment:
Drug: Pembrolizumab
Drug: SKB264

Trial contacts and locations

48

Loading...

Central trial contact

Jin Xiaoping

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems